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ABSTRACT
OBJECTIVE: To evaluate the impact of the expansion of access to medicines by the Programa 
Farmácia Popular do Brasil (PFPB – Brazilian Popular Pharmacy Program) on the indicators 
of hospitalizations and deaths by hypertension and diabetes.
METHODS: To estimate the impact of the Brazilian Popular Pharmacy Program, the statistical 
model of fixed-effect difference in differences was used, considering: the divisions Rede Própria 
(RP – Proprietary Network) and Rede Conveniada (RC – Partnership Network); the exposure 
time of the municipality to the program; intramunicipal density, measured by the number of 
accredited establishments; and the coverage spillover effect into patients from nonparticipating 
municipalities. Data from 5,566 municipalities were used, for the period from 2003 to 2016, 
including: (i) administrative records of the PFPB, Sistema de Informações sobre Mortalidade (SIM 
– Information System on Mortality), and Sistema de Informações Hospitalares (SIH – Hospital 
Information System); ii) other health data managed by the Departamento de Informática do SUS 
(DATASUS – Department of Informatics of SUS); iii) sociodemographic data produced by the 
Brazilian Institute of Geography and Statistics (IBGE); and iv) data from the Relação Anual de 
Informações Sociais (RAIS – Annual List of Social Information).
RESULTS: The expansion of access to medicines for treatment of hypertension and diabetes 
resulted in a meaningful and statistically significant reduction (p < 0.05) of the number of 
hospitalizations and deaths by these diseases, in an average annual rate of 27.6% and 8.0%, 
respectively. The observed impacts were induced by the partnership network, highlighting 
the density of establishments per 100,000 inhabitants and, above all, the exposure time of the 
municipality to the program as relevant to the effect. Evidence of a spillover effect and of the 
maintenance of impacts on different age groups, especially older people, were also observed.
CONCLUSIONS: The strategy to expand access to medicines through the PFPB was effective 
in reducing hospitalizations and deaths by hypertension and diabetes in Brazil during the 
investigated period. Better understanding the impacts of the program is important to improve 
the pharmaceutical care policy, to ensure access to cost-effective treatments.
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INTRODUCTION
In Brazil, chronic noncommunicable diseases (CNCDs) were responsible for 73% of deaths 
in 20161. According to the Plan of Strategic Actions for Fighting CNCDs in Brazil from 2011 
to 2022, hypertension and diabetes are the main causes of morbidity and mortality in the 
country, with high social and economic impacts2.
Pharmacological treatment integrated to primary health care is one of the most cost-effective 
ways to address cardiovascular diseases, including hypertension and diabetes. Currently, 
the Brazilian Unified Health System (SUS) ensures pharmacological treatment for these 
diseases in two ways: Basic Pharmacies, which are basic dispensing units of the Brazilian 
Unified Health System (SUS) in primary health care; and the PFPB.
The PFPB was thought of as a complement to the dispensation of medicines covered by Basic 
Pharmacies and operated in two divisions until 2017. The first was the Proprietary Network 
(RP), which came into operation in 2004 and was closed in 2017. It was managed by Fiocruz 
and included public pharmacies and drugstores installed by partnerships with municipal 
and state governments and nonprofit organizations to distribute medicines with copayment 
of a small portion or for free – which is the case of medicines for the treatment of diabetes, 
hypertension and asthma from 2011 on. The second is the Partnership Network (RC), which 
has been in operation since March 2006 and uses the capillarity of pharmacies from the 
private network to distribute medicines with copayment; since 2011, it also dispenses the 
medicines for hypertension, diabetes, and asthma for free.
Despite being implemented for over a decade, studies on PFPB are still scarce, and reviews 
about its impact on the health conditions of its beneficiaries are even more rare. Regarding 
impact evaluations, we highlight the study of Ferreira3, which uses municipal data from 
2000 to 2012 to analyze the effects of distribution of medicines by the partnership network 
(PFPB-RC). The findings show the PFPB-RC reduces mortality rates by circulatory diseases 
and dyslipidemia, and that the addition of a partnership unit to every 100,000 inhabitants 
generates a reduction of 3.5 and 4.5 in the hospitalization rate for diabetes and hypertension 
per 100,000 inhabitants, respectively. The study also shows that the effects of the program 
increase with the age of the beneficiary, mainly from the age of 40.
Despite its importance, the analysis developed by Ferreira3 leaves open some relevant issues, 
such as the role of each part of the program and the heterogeneity of the effects over time, 
which can affect the conclusions on the PFPB effectiveness. Thus, this study aims to move 
forward on these issues, having as main objective to evaluate the role of expanding the 
supply of medicines by PFPB in its divisions RP and RC on indicators of hospitalizations and 
deaths by hypertension and diabetes. The specific analysis for these diseases is motivated 
by their importance among the major CNCDs, as well as by the fact that medicines for their 
treatment are included in the PFPB since its implementation in 2004, historically accounting 
for more than 70% of the spending with the program.
METHODS
To estimate the PFPB impact, the statistical model of fixed-effect difference in differences 
was used, considering: the divisions of RP and RC; the exposure time of the municipality to 
the program; intramunicipal density, measured by the number of accredited establishments; 
and the coverage spillover effect.
Annual data from 5,566 Brazilian municipalities (99.9% of the municipalities in the country) 
were used. The initial research period is 2003, the year before the start of PFPB, and the final 
period was defined by data availability: 2016 for the analysis of the effects of the program 
on hospitalization rates and 2015 for mortality rates.
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The outcome variables, rates of hospitalization and mortality by diabetes and hypertension 
per 100,000 inhabitants, were constructed from data of SIH and SIM, considering the codes 
of the International Classification of Diseases (ICD-10) related to the two diseases on the 
quantification of hospitalizations and deaths, in addition to the population estimates of 
IBGE. The explanatory variables of interest for this evaluation are related to the specificities 
of the program coverage. To better characterize this coverage, administrative data of 
the PFPB were used regarding participating establishments, such as location, date of 
accreditation, division (RP or RC), and monthly transfer flow of the program.
Thus, the impacts of the program were measured considering: 1) exposure time by type 
of division, defined by the amount of years in which the municipality had establishments 
of RC or RP with sales record of PFPB items; 2) coverage density, measured by the annual 
amount of establishments of the program per 100,000 inhabitants in each covered 
municipality; 3) the coverage spillover effect, measured by the number of municipalities, 
close to a noncovered municipality, that have establishments accredited to the program 
in a given period of time.
If, on the one hand, the exposure time captures the maturation of the PFPB impacts on 
the health status of the population, on the other, one must consider the density of coverage 
within the municipality. For example, there may be locations with identical times of 
exposure, but with different numbers of proprietary or partnership establishments per 
100,000 inhabitants, and this difference affects the probability of access to medicine. 
Furthermore, considering that most of the Brazilian municipalities are small, the absence 
of PFPB in a given municipality does not necessarily implies that its residents cannot have 
access to medicines in neighboring municipalities covered by the program.
To better estimate the effects attributable to the PFPB, other explanatory variables were 
used, which can be responsible for the differences in results not directly related to the 
program and that can also affect the participation decision of establishments. These control 
variables increase the precision of the estimates of the program effects and also reduce 
possible selection biases4,5. Such biases are related to the nonmandatory character of the 
adherence to PFPB, so that locations with establishments of the program could present 
economic, social, demographic, and business characteristics different from those of the 
regions without accredited establishments. Thus, thinking about the eligibility criteria 
for adherence to the PFPB, variables that include population size (important for the RP, 
which was prioritized in places with greater population) and number of pharmacists (one 
of the criteria for accreditation) were used, while for the decision of accreditation of private 
establishments, commercial dimension proxies were also considered, such as size of the 
local market (given by the salaries of formal workers) and competition (total number of 
drugstores). Moreover, number of medical consultations in primary health care, number 
of hospital beds, number of higher education schools (a proxy for the education level of the 
municipality), and average income of formal workers were also included in the regression 
models, since they can affect the indicators of hospitalizations and deaths. All these variables 
are from DATASUS, RAIS, and IBGE.
In statistical terms, regression models with panel data were adjusted, using fixed effect 
and the difference in differences (DiD) estimator6,7. This approach allows one to control the 
non-observed time invariant heterogeneity, because municipalities covered by the program 
can be distinct from those not covered, and these differences can be correlated with the 
outcome indicators (hospitalizations and deaths).
Considering that individuals living in municipalities exposed longer to the PFPB, for 
having easier access, are more likely to adhere to the pharmacological treatment7, the 
basic specification of the model incorporates the scheduling of the coverage between the 
municipalities to measure effectiveness according to exposure time. It is also assumed 
that the municipal health indicators are mainly determined by demographic, social, and 
economic factors, as well as by health care, which includes pharmaceutical care8,9.
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Equation 1 highlights the main model to evaluate the PFPB effects on population 
health indicators.
Equation 1
Yit,k = 
J
Σ
j=1
 βj,k RCj,it +   
G
Σ
g=1
 δg,kRPg,it + τ1,kEstbit + τ2,kNBit + X'it γk + ϕi + μst + ϵit,k
where Yit,k represents the indicator of result k for municipality i at time t, with k including 
the indicators of hospitalization and mortality; RCj,it is a binary variable that takes a value 
of one if municipality i in year t had any private establishment with sales record in the 
partnership network of the program for j years; RPg,it is a binary variable that takes a value 
of one if the municipality i in year t had some establishment of RP with sales record for g 
years; Estbit captures the number of establishments of the program per 100,000 inhabitants, 
given that the coverage density can vary over time; NBit measures its spillover effect by the 
number of neighbors of municipality i, in a radius of 50 km, covered by the PFPB at a time 
t; Xit represents a vector of control variables of the municipalities; ϕi is the fixed effect of 
the municipality, μst represents temporal trends specific for the s-th federation unit of the 
municipality location; ϵit,k is the random error term.
RESULTS
Table 1 shows the estimated impacts of the PFPB on hospitalization and mortality by 
hypertension and diabetes. One can observe that the effects of the program on the two 
outcome variables are statistically significant (p < 0.05) only for RC. For example, in 10 years 
of exposure to this program division, the municipalities have reduced, on average, 100.3 
hospitalizations per 100,000 inhabitants and 13.3 deaths per 100,000 inhabitants resulting 
from the two diseases.
Coverage density is an important variable in the analysis. The increase of a partnership 
establishment by 100,000 inhabitants, by itself, is able to reduce on average 0.69 hospitalizations 
per 100,000 inhabitants, with an equivalent elasticity of -1.6%. That is, a magnification of 
1% in the number of establishments in a municipality decreases, on average, the rate of 
hospitalization by hypertension and diabetes in 1.6%.
Additionally, the results show that municipalities without PFPB coverage that are neighbors 
of covered municipalities are also benefited, with an average reduction of 7.9 hospitalizations 
per 100,000 inhabitants and 0.6 deaths per 100,000 inhabitants, indicating spillover effect 
of the program coverage.
To detail the previous results, Tables 2 and 3 present the PFPB effects on hospitalization and 
mortality rates per 100,000 inhabitants, respectively, by age groups, diseases, and program 
divisions. Both tables do not show statistically significant effects (different from zero with 
a 5% significance level) of RP on the analyzed outcomes.
Considering the two diseases, the effectiveness of RC on the reduction of hospitalizations 
is higher for the older age groups; is more significant for hypertension than for diabetes; 
and grows according to the exposure time of the municipalities to the PFPB (Table 2). 
In 2016, for municipalities covered for 11 years, the program was able to reduce 50.7 
hospitalizations per 100,000 inhabitants for individuals with 60 years or more and living 
in the covered municipalities (for the two diseases). In all age groups, the reduction was of 
49.6 hospitalizations per 100,000 inhabitants for hypertension.
Regarding mortality, the effectiveness of the program is lower (Table 3). The reduction in 
the mortality rate among individuals with 60 years or more was of 9.9 deaths per 100,000 
inhabitants in the municipalities covered for more time (tenth year, from 2006 to 2015) by 
RC. However, unlike what was observed for hospitalizations, considering all age groups, 
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the reduction of the mortality rate was more significant for diabetes than for hypertension, 
with a decrease of 8.4 deaths against 4.9 deaths per 100,000 inhabitants in the same year.
The PFPB spillover effect is also statistically significant for the estimated mortality reduction 
coefficients: in the case of hypertension, for all age groups; in the case of diabetes, only for 
Table 1. Estimated impact of the Brazilian Popular Pharmacy Program on the rates of hospitalization 
(2003–2016) and mortality (2003–2015) by diabetes and hypertension, according to the exposure time 
of the municipalities to the program and its divisions. Rates per 100,000 inhabitants.
Explanatory variables of interest
Dependent variables
Hospitalization Mortality
Partnership network (RC)
Exposure time
1st year -23.68* (273) -2.89* (0.63)
2nd year -29.87* (2.93) -3.51* (0.68)
3rd year -39.44* (3.20) -3.30* (0.76)
4th year -51.49* (3.48) -3.61* (0.83)
5th year -59.65* (3.80) -6.50* (0.91)
6th year -68.66* (4.16) -7.25* (1.04)
7th year -75.67* (4.66) -8.81* (1.17)
8th year -82.86* (5.23) -9.58* (1.38)
9th year -94.25* (6.13) -10.33* (1.59)
10th year -100.29* (7.05) -13.31* (2.09)
11th year -91.67* (9.25) -
Proprietary network (RP)
Exposure time
1st year 17.33* (7.57) 1.15 (1.70)
2nd year 15.97* (7.61) 1.84 (1.72)
3rd year 8.03 (7.68) 1.68 (1.73)
4th year 5.30 (7.73) 1.70 (1.74)
5th year 4.89 (7.77) 3.17 (1.78)
6th year 3.90 (7.94) 2.97 (1.83)
7th year 4.12 (8.15) 2.92 (1.89)
8th year 3.90 (8.41) 3.46 (2.01)
9th year 3.50 (8.92) 4.44 (2.32)
10th year 1.19 (10.30) 5.53 (3.30)
11th year 12.47 (14.64) 9.99 (7.48)
12th year 28.42 (32.95) 12.07 (16.80)
13th year 3.45 (73.92)
Coverage density (Estb) -0.69* (0.06) -0.01 (0.01)
Spillover effect (NB) -7.91* (0.68) -0.58* (0.16)
Tendency (μ) X X
Controls (X) X X
Fixed effect (ϕ) X X
Period (years) 14 13
Municipalities 5,566 5,566
* Value statistically different from zero (p < 0.05).
Note: Robust standard errors are clustered at the level of the municipality in parentheses. The tendency (μ) is 
represented by binary variables of years, specific to each Federative Unit. The controls (X) used were size of the 
population living in the municipality, number of pharmacists per 100,000 inhabitants, salaries of formal workers, 
number of pharmacies (total and per 100,000 inhabitants), medical consultations in primary health care per 
100,000 inhabitants, number of hospital beds per 100,000 inhabitants, number of higher education facilities per 
100,000 inhabitants, and average income of formal workers. The fixed effect (ϕ), one of the features of the panel 
data regression model, controls all unobservable factors invariant in time.
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older people. Regarding hospitalization, municipalities without program coverage, but 
neighbors of covered municipalities, can reduce the hospitalization rate in all age groups 
and for both diseases.
The Figure summarizes the marginal effect of the PFPB over time, considering the estimates 
of Tables 1, 2, and 3 with 5% statistical significance level.
Table 2. Estimated impact of the Brazilian Popular Pharmacy Program on hospitalization rate, by age 
group, disease, and division of the program. Brazil, 2003–2016. Rates per 100,000 inhabitants.
Explanatory variables of interest
Age group (years) Disease
26 to 39 40 to 59 60 or more Diabetes Hypertension
Partnership network (RC)
Exposure time
1st year -2.13* -8.20* -12.20* -3.34* -20.33*
2nd year -2.01* -10.06* -17.01* -7.08* -22.79*
3rd year -2.78* -13.53* -22.11* -10.72* -28.72*
4th year -3.53* -18.59* -27.65* -16.92* -34.57*
5th year -3.72* -20.97* -32.79* -21.67* -37.98*
6th year -4.65* -24.33* -37.62* -26.30* -42.36*
7th year -4.94* -27.85* -40.91* -30.15* -45.52*
8th year -5.02* -29.95* -46.06* -36.91* -45.94*
9th year -4.07* -34.56* -54.22* -42.83* -51.41*
10th year -5.27* -36.80* -56.85* -46.37* -53.92*
11th year -3.63* -36.12* -50.67* -42.04* -49.63*
Proprietary network (RP)
Exposure time
1st year 2.21 5.69 6.99 1.64 15.68*
2nd year 1.76 5.22 7.41 2.07 13.90*
3rd year 0.44 1.97 5.01 1.93 6.1
4th year -0.47 1.01 5.27 1.89 3.41
5th year -0.7 1.28 5.39 1.89 2.99
6th year -0.26 2.13 3.18 0.99 2.91
7th year -0.22 1.58 4.08 1.35 2.77
8th year -0.5 1.32 3.11 1.78 2.11
9th year -0.44 1.06 3.93 1.59 1.91
10th year -0.98 0.67 3.66 1.05 0.13
11th year -0.69 6.88 8.78 1.48 10.99
12th year -0.35 13.52 19.53 7.43 20.99
13th year -3.41 -4.29 11.42 -0.73 4.18
Coverage density (Estb) -0.03* -0.26* -0.43* -0.37* -0.32*
Spillover effect (NB) -0.44* -2.61* -4.57* -1.55* -6.37*
Tendency (μ) X X X X X
Controls (X) X X X X X
Fixed effect (ϕ) X X X X X
Period (years) 14 14 14 14 14
Municipalities 5,566 5,566 5,566 5,566 5,566
* Value statistically different from zero (p < 0.05).
Note: Robust standard errors are clustered at the level of the municipality in parentheses. The tendency (μ) is 
represented by binary variables of years, specific to each federation unit where the municipality is located. The 
controls (X) used were size of the population living in the municipality, number of pharmacists per 100,000 
inhabitants, salaries of formal workers, number of pharmacies (total and per 100,000 inhabitants), medical 
consultations in primary health care per 100,000 inhabitants, number of hospital beds per 100,000 inhabitants, 
number of higher education facilities per 100,000 inhabitants, and average income of formal workers. The 
fixed effect (ϕ), one of the features of the panel data regression model, controls all unobservable factors 
invariant in time.
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The effectiveness indicator is the percentage reduction rate of hospitalizations and deaths by 
hypertension and diabetes. The PFPB was able to reduce the number of hospitalizations and 
deaths in SUS, respectively, at 27.6% and 8.0% per year, on average, for the period investigated. 
By the disease-specific estimates, we observed a similar behavior on the trajectory of the 
program effectiveness. For hypertension, the annual average reduction of hospitalizations 
and deaths was respectively of 33.7% and 8.8%, and for diabetes, 21.8% and 7.5%, during 
the period of analysis.
Table 3. Estimated impact of the Brazilian Popular Pharmacy Program on death rate, by age group, 
disease, and division of the program. Brazil, 2003–2016. Rates per 100,000 inhabitants.
Explanatory variables of interest
Age group (years) Disease
26 to 39 40 to 59 60 or more Diabetes Hypertension
Partnership network (RC)
Exposure time
1st year -0.10 -0.33 -2.28* -1.18* -1.71*
2nd year -0.12 -0.40 -2.92* -1,62* -1.88*
3rd year -0.23* -0.20 -2.76* -1.33* -1.97*
4th year -0.15 -0.71* -2.49* -1.50* -2.11*
5th year -0.23* -0.88* -5.28* -3.50* -3.01*
6th year -0.31* -1.01* -5.89* -3.95* -3.29*
7th year -0.31* -1.20* -7.26* -4.90* -3.90*
8th year -0.39* -1.42* -7.50* -6.14* -3.44*
9th year -0.34 -1.84* -7.98* -6.11* -4.22*
10th year -0.47 -2.18* -9.93* -8.44* -4.87*
Proprietary network (RP)
Exposure time
1st year 0.10 0.09 0.33 1.00 0.15
2nd year 0.17 0.53 0.75 1.43 0.41
3rd year 0.02 0.19 0.89 1.17 0.51
4th year -0.002 0.31 0.53 1.57 0.13
5th year -0.01 0.95 2.19 2.05 1.11
6th year 0.07 0.61 1.15 1.94 1.03
7th year 0.07 0.69 1.76 2.10 0.82
8th year 0.05 0.63 2.66 2.38 1.09
9th year 0.09 0.83 2.95 3.14* 1.30
10th year -0.004 1.33 4.15 2.97 2.56
11th year 0.22 0.82 6.56 5.85 4.13
12th year 0.20 3.68 14.02 6.66 5.41
Coverage density (Estb) 0.0002 0.001 -0.02 -0.02 0.002
Spillover effect (NB) -0.03 -0.09 -0.46* -0.06 -0.53*
Tendency (μ) X X X X X
Controls (X) X X X X X
Fixed effect (ϕ) X X X X X
Period (years) 13 13 13 13 13
Municipalities 5,566 5,566 5,566 5,566 5,566
* Value statistically different from zero (p < 0.05).
Note: Robust standard errors are clustered at the level of the municipality in parentheses. The tendency (μ) is 
represented by binary variables of years, specific to each federation unit where the municipality is located. The 
controls (X) used were size of the population living in the municipality, number of pharmacists per 100,000 
inhabitants, salaries of formal workers, number of pharmacies (total and per 100,000 inhabitants), medical 
consultations in primary health care per 100,000 inhabitants, number of hospital beds per 100,000 inhabitants, 
number of higher education facilities per 100,000 inhabitants, and average income of formal workers. The 
fixed effect (ϕ), one of the features of the panel data regression model, controls all unobservable factors 
invariant in time.
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DISCUSSION
Although initially designed as a complement to the dispensation of continuous-use 
medicines in pharmacies of SUS primary health care services, the demand for medicines 
and the expense with PFPB have quickly grown in recent years. In 2016, the expenses with 
PFPB were over 2.7 billion reals, which corresponds to more than double the amount spent 
by the Ministry of Health with medicines dispensed in primary health care10. The list of 
the program includes medicines for treatment of several CNCDs, but more than 71% of the 
resources were spent on hypertension and diabetes drugs that year.
Some studies have shown that the costs of the provision of medicines in SUS pharmacies may 
be lower than by the PFPB11,12. In this scenario, questions on the effectiveness of the program 
become relevant. As a rule, the evidence presented here suggest that improvement of access 
to the medicines covered by the program affected the adherence to the pharmacological 
treatment, regardless of the age group. This confirms the importance of access to medicines 
for obtaining better results in health, enabling greater population survival and lower costs 
for the health system13,14.
Given that there are problems of access to medicines by SUS patients, regardless of age 
or health group or evaluated health condition15, the results indicate that the expansion of 
availability has resulted in a significant reduction of hospitalizations and deaths – on average 
27.6% and 8.0%, respectively, in the period of analysis. This finding shows the importance 
of ensuring access to pharmaceutical products by the public sector. This is particularly 
relevant in Brazil, considering that families with less income proportionally spend more 
on healthcare than those with higher income, and spending on medicines have a major 
stake in these expenses16,17.
From the PFPB divisions, RC was responsible for the impacts observed, being relevant 
to the effect the exposure time of the municipalities to the program and the density of 
establishments per 100,000 inhabitants. There is also evidence of program spillover effect, 
Developed estimates based on coefficients of Tables 1, 2, and 3, considering a 5% statistical significance level and the overall effect of the program on the 
three aspects evaluated (exposure time, coverage density, and spillover effect).
Figure. Rate of change of hospitalizations (a) and deaths (b) after implementation of the Brazilian Popular Pharmacy Program, total and by 
disease. Brazil, 2003–2016.
(A) Hospitalizations (2003 to 2016) (B) Mortality (2003 to 2015)
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which means that even the population of municipalities that do not have accredited 
pharmaceutical establishments benefit from the program by having access to medicines 
in neighboring municipalities.
Concerning the non-identification of impacts in RP, it is important to note that this finding 
may be related to its low capillarity (reduced coverage and density). In 2016, only 7.3% of the 
municipalities had pharmacies linked to RP, with less than one establishment per 100,000 
inhabitants. On the other hand, RC was present in most municipalities, with 82% coverage 
and average density of 17 establishments per 100,000 inhabitants.
Another issue is that RP may have a lower availability of medicines for hypertension 
and diabetes compared to RC18. In addition, considering its low capillarity, from the 
methodological point of view, the evaluation of the effectiveness of RP would be more 
appropriate if done with users rather than municipalities.
Regarding the expressive effects induced by RC on hospitalization and mortality indicators, 
one observes this division presents high coverage on national territory – with high 
intramunicipal density –, variety of brands, and availability of medicines for users18. Since 
an expressive part of the demand is formed by SUS patients19 (about 70% in 2014), the PFPB 
may be filling a gap in the public system itself, because of problems with the provision of 
medicines by municipal and state governments13,19,20.
Using data from the 2013 Pesquisa Nacional de Saúde (PNS – National Health Survey), 
Costa et al.21 have shown that 35.9% of hypertensive and 57.4% of diabetic individuals 
have obtained at least one medicine from the PFPB, with emphasis on the participation of 
socioeconomically disadvantaged segments. In this sense, as RC leverages the structure 
and distribution logistics network of drug stores and pharmacies in retail, it manages to 
provide access to medicines to a large group of individuals with difficulties to get them 
from SUS pharmacies and, thus, makes the continued treatment of the studied chronic 
diseases more effective.
The underestimation of the program effects in the absence of the variable that captures the 
overflow of its coverage may be related to the contamination of the group of non-covered 
municipalities, since the people living there can access the medicines in PFPB establishments 
from other municipalities. Considering that Brazil is formed by a large number of small 
municipalities (about 70% have less than 20000 inhabitants), and that there is a growing 
trend of commuting, it is likely that there is a potential demand for medicines and other 
items provided in neighboring municipalities. The inclusion of this variable in the model 
proved to be important.
The results of this study confirm the findings of Ferreira3, to the extent that the 
estimated coefficients in both studies have the same sign. The previous study identified 
as effect of the PFPB-RC the reduction of 3.5 and 4.5 hospitalizations per 100,000 
inhabitants, respectively, for diabetes and hypertension. However, the coefficients 
shown in Table 2 of this article, as a whole, are much larger (in absolute terms) and 
more robust, especially for individuals aged 40 years or more, confirming the need 
to consider the time of exposure to continued treatment and to control the possible 
spillover effect of the program coverage. Comparing these findings, we concluded that 
the program was able to reduce, over time, more hospitalizations and deaths related 
to hypertension than diabetes.
In general, the findings show positive aspects of the program. However, even if its 
effectiveness is proven, the impacts of the replacement of pharmaceutical care for PFPB in 
primary health care must be investigated in further studies. Since most medicines of the 
program are on the Relação Nacional de Medicamentos Essenciais (RENAME – National List 
of Essential Medicines)22, it may encourage health secretaries not to buy them, especially 
at a time of economic recession and budget constraint, besides encouraging the suppliers 
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not to take part in the bidding processes of prefectures, which have a higher risk of default, 
while the program involves a single payera.
The limitations of this study include the fact that hospitalizations by hypertension and 
diabetes in the private health subsystem were not considered, which creates some uncertainty 
about the effectiveness of the program measured by the number of hospitalizations averted, 
unlike the effectiveness estimated as reduction of deaths, which is methodologically robust. 
Another limitation concerns the data used, which were not able to properly evaluate the 
effectiveness of RP, considering its low capillarity in the municipalities.
Finally, it should be noted that the analysis can be improved by future research. For 
instance, it would be possible to estimate disability-adjusted life years (DALYs), from data 
of individuals, and measure the effectiveness of the program by the number of averted 
DALYs. Based on this indicator and on information about the costs of the program, it would 
be possible to estimate its cost-effectiveness ratio and apply the parameter of the World 
Health Organization to evaluate the PFPB in this regard23,24.
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